GSK certifies all antibiotic manufacturing sites against AMR standard

The firm has become the first pharma company to achieve BSI Kitemark certification for minimising antimicrobial resistance risk across its entire global antibiotic manufacturing network

GSK has become the first pharmaceutical company to achieve BSI Kitemark certification for minimising the risk of antimicrobial resistance (AMR) at all its antibiotic manufacturing sites across the world.

The announcement comes during World AMR Awareness Week and follows certification of the company's final site, which GSK says meets its commitment to have its entire antibiotic manufacturing network independently assessed by the end of 2026.


Developed by the British Standards Institution (BSI) in collaboration with the AMR Industry Alliance (AMRIA), the Kitemark verifies that manufacturers appropriately control wastewater streams to minimise the release of APIs into the environment.

Uncontrolled antibiotic residues entering waterways and surrounding ecosystems can encourage the development and spread of drug-resistant bacteria, potentially compromising the effectiveness of existing treatments.

Certification involves an initial assessment against the AMRIA Antibiotic Manufacturing Standard — published in May 2025 — followed by annual surveillance to verify that appropriate controls remain in place.


GSK's Worthing site became the first UK facility to achieve the certification in September 2024.

The company subsequently extended certification across its manufacturing network, with five additional sites completing the process in the last year.

The achievement comes as scrutiny of pharma supply chains and their contribution to AMR continues to increase.

The World Health Organization (WHO) identifies AMR as one of the leading global public health threats, while the Access to Medicine Foundation's 2026 AMR Benchmark recognised GSK as one of only three companies reporting compliance with antibiotic discharge limits across both its internal manufacturing operations and external suppliers.

Regis Simard, President of Global Supply Chain at GSK, said: "Achieving BSI Kitemark certification for all of our antibiotic manufacturing sites is a clear demonstration of GSK’s commitment to addressing AMR."

"As the first pharmaceutical company to reach this milestone, it reflects our dedication to responsible manufacturing and reducing our environmental impact."

This isn’t just about meeting rigorous standards; it’s about setting a new benchmark for the industry and ultimately ensuring that patients around the world can continue to rely on the essential medicines they need.

Wider sustainability commitments

GSK's AMR certification programme forms part of a broader effort to improve environmental performance across its global manufacturing and supply chain operations.

In its 2025 Responsible Business Report, the company reported that 100% of its manufacturing sites and key suppliers had API discharges below predicted no-effect concentration levels, as defined by AMRIA and its wastewater discharge limits.

It also confirmed that all its own sites remained within the relevant discharge limits. 

The company's progress was also recognised in the Access to Medicine Foundation's March 2026 AMR Benchmark.

GSK was highlighted alongside Aurobindo and Sandoz for reporting compliance with antibiotic waste limits across both in-house and supplier manufacturing for all its antimicrobial products. 

You may also like